Last reviewed · How we verify
Thiapride (TIAPRIDE)
Thiapride works by blocking the D(4) dopamine receptor, which helps to regulate mood and reduce symptoms of certain psychiatric conditions.
Thiapride (TIAPRIDE) is a small molecule drug that targets the D(4) dopamine receptor, classified as a tiapride. It is used to treat certain psychiatric conditions, although its exact approved indications are unknown. Thiapride's commercial status is unclear, with unknown patent status and generic manufacturers. The drug has a half-life of 3.2 hours, but its bioavailability is unknown. As a result, its availability and usage may be limited.
At a glance
| Generic name | TIAPRIDE |
|---|---|
| Drug class | tiapride |
| Target | D(4) dopamine receptor, Alpha-2A adrenergic receptor, D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Think of dopamine like a messenger in your brain that helps you feel happy and focused. When there's too much dopamine, it can cause problems like anxiety and agitation. Thiapride helps by blocking the D(4) dopamine receptor, which reduces the amount of dopamine that's active in the brain and helps to calm symptoms.
Approved indications
Common side effects
- Extrapyramidal disorder
- Neuroleptic malignant syndrome
- Altered state of consciousness
- Somnolence
- Parkinsonism
- Dyskinesia
- Confusional state
- Coma
- Fall
- Hepatic fibrosis
- Hepatic haematoma
- Drug interaction
Key clinical trials
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride (PHASE3)
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- Phase III Study of 5LGr to Treat Tic Disorder (PHASE3)
- Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thiapride CI brief — competitive landscape report
- Thiapride updates RSS · CI watch RSS